Hematology — Acute and Chronic Leukemias

Internal Medicine · Clinical Specialties

How it begins

Molecular biology, WHO 2022 classification, ELN risk stratification, immunophenotypic and cytogenetic diagnosis, targeted treatment with tyrosine kinase inhibitors and BCL-2 inhibitors, hematopoietic stem cell transplantation and minimal residual disease

What it covers

1. Normal Hematopoiesis and Pathogenesis of Leukemias
2. · Molecular Mechanisms of Leukemic Transformation
3. Acute Myeloid Leukemia (AML)
4. · WHO 2022 AML Classification
5. · ELN Risk Stratification 2022
6. · Diagnosis of AML — Minimum Mandatory Panel
7. · Treatment of AML
8. Acute Promyelocytic Leukemia (APL / APL)
9. · APL treatment — ATRA + ATO
10. Acute Lymphoblastic Leukemia (ALL)
11. · Classification and Immunophenotype of ALL
12. · Philadelphia-positive ALL (Ph+ ALL) — The Great Prognostic Change with ITK
13. · General Treatment of ALL — Phases
14. Chronic Myeloid Leukemia (CML)
15. · Phases of the CML
16. · Tyrosine Kinase Inhibitors (TKI) in CML
17. · Response and Monitoring Definitions
18. Chronic Lymphocytic Leukemia (CLL)
19. · Staging — Rai and Binet
20. · Genomic Prognostic Factors in CLL — The Mandatory Molecular Panel
21. · Treatment Indications (iwCLL 2018)
22. · Current Treatment of CLL
23. Rare Leukemias and Special Variants
24. · Prolymphocytic Leukemia (LPL-B and LPL-T)
25. Hematopoietic Stem Transplantation (HSCT / TCPH)
26. · Types of Transplant
27. · Graft versus Host Disease (GVHD/GvHD)
28. Integrative Clinical Correlations
29. · Hematological Emergencies in Leukemias
30. · Comparison of Major Leukemias
31. · Integrating Principle — Hematology Oncology of the 21st Century